CANOPY GROWTH CORP (CGC)

CA1380357048 - Common Stock

2.22  -0.17 (-7.11%)

After market: 2.22 0 (0%)

Fundamental Rating

2

CGC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of CGC have multiple concerns. CGC has a expensive valuation and it also scores bad on growth.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CGC has reported negative net income.
In the past year CGC has reported a negative cash flow from operations.
In the past 5 years CGC always reported negative net income.
In the past 5 years CGC always reported negative operating cash flow.

1.2 Ratios

CGC has a worse Return On Assets (-45.81%) than 60.75% of its industry peers.
The Return On Equity of CGC (-110.77%) is worse than 61.29% of its industry peers.
Industry RankSector Rank
ROA -45.81%
ROE -110.77%
ROIC N/A
ROA(3y)-63.49%
ROA(5y)-47.06%
ROE(3y)-181.56%
ROE(5y)-123.98%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

CGC has a Gross Margin of 31.47%. This is comparable to the rest of the industry: CGC outperforms 54.84% of its industry peers.
In the last couple of years the Gross Margin of CGC has grown nicely.
The Profit Margin and Operating Margin are not available for CGC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 31.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.93%
GM growth 5Y16.63%

More info and screens

3

2. Health

2.1 Basic Checks

CGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CGC has been reduced compared to 1 year ago.
The number of shares outstanding for CGC has been reduced compared to 5 years ago.
Compared to 1 year ago, CGC has an improved debt to assets ratio.

2.2 Solvency

CGC has an Altman-Z score of -9.27. This is a bad value and indicates that CGC is not financially healthy and even has some risk of bankruptcy.
CGC's Altman-Z score of -9.27 is on the low side compared to the rest of the industry. CGC is outperformed by 73.12% of its industry peers.
A Debt/Equity ratio of 0.85 indicates that CGC is somewhat dependend on debt financing.
CGC has a worse Debt to Equity ratio (0.85) than 71.51% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF N/A
Altman-Z -9.27
ROIC/WACCN/A
WACC9.91%

2.3 Liquidity

CGC has a Current Ratio of 1.39. This is a normal value and indicates that CGC is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.39, CGC is not doing good in the industry: 76.88% of the companies in the same industry are doing better.
A Quick Ratio of 1.07 indicates that CGC should not have too much problems paying its short term obligations.
The Quick ratio of CGC (1.07) is worse than 77.42% of its industry peers.
Industry RankSector Rank
Current Ratio 1.39
Quick Ratio 1.07

More info and screens

3

3. Growth

3.1 Past

CGC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.30%, which is quite impressive.
Looking at the last year, CGC shows a very negative growth in Revenue. The Revenue has decreased by -12.56% in the last year.
The Revenue has been growing slightly by 5.60% on average over the past years.
EPS 1Y (TTM)63.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.58%
Revenue 1Y (TTM)-12.56%
Revenue growth 3Y-18.39%
Revenue growth 5Y5.6%
Sales Q2Q%-23.25%

3.2 Future

Based on estimates for the next years, CGC will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.34% on average per year.
The Revenue is expected to grow by 3.39% on average over the next years.
EPS Next Y60.39%
EPS Next 2Y36.48%
EPS Next 3Y23.6%
EPS Next 5Y13.34%
Revenue Next Year-16.99%
Revenue Next 2Y-7.83%
Revenue Next 3Y-0.55%
Revenue Next 5Y3.39%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CGC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CGC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as CGC's earnings are expected to grow with 23.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.48%
EPS Next 3Y23.6%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CGC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CANOPY GROWTH CORP

NASDAQ:CGC (1/14/2025, 5:31:45 PM)

After market: 2.22 0 (0%)

2.22

-0.17 (-7.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-08 2024-11-08/bmo
Earnings (Next)02-07 2025-02-07/bmo
Inst Owners8.79%
Inst Owner Change0%
Ins Owners0.06%
Ins Owner Change-8.66%
Market Cap300.14M
Analysts48.42
Price Target4.33 (95.05%)
Short Float %7.5%
Short Ratio1.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-235.69%
Min EPS beat(2)-240.27%
Max EPS beat(2)-231.12%
EPS beat(4)0
Avg EPS beat(4)-253.93%
Min EPS beat(4)-418.91%
Max EPS beat(4)-125.4%
EPS beat(8)1
Avg EPS beat(8)-223.97%
EPS beat(12)2
Avg EPS beat(12)-201.16%
EPS beat(16)4
Avg EPS beat(16)-193.96%
Revenue beat(2)0
Avg Revenue beat(2)-4.2%
Min Revenue beat(2)-8.11%
Max Revenue beat(2)-0.3%
Revenue beat(4)2
Avg Revenue beat(4)1.81%
Min Revenue beat(4)-8.11%
Max Revenue beat(4)12.74%
Revenue beat(8)3
Avg Revenue beat(8)-0.28%
Revenue beat(12)5
Avg Revenue beat(12)-2.42%
Revenue beat(16)6
Avg Revenue beat(16)-3.23%
PT rev (1m)-12.47%
PT rev (3m)-32.37%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-38.02%
EPS NY rev (1m)0%
EPS NY rev (3m)-49.49%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-13.17%
Revenue NY rev (1m)3.09%
Revenue NY rev (3m)-4.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.54
P/FCF N/A
P/OCF N/A
P/B 0.85
P/tB 1.17
EV/EBITDA N/A
EPS(TTM)-4.67
EYN/A
EPS(NY)-0.82
Fwd EYN/A
FCF(TTM)-0.86
FCFYN/A
OCF(TTM)-0.82
OCFYN/A
SpS1.44
BVpS2.62
TBVpS1.9
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.81%
ROE -110.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 31.47%
FCFM N/A
ROA(3y)-63.49%
ROA(5y)-47.06%
ROE(3y)-181.56%
ROE(5y)-123.98%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.93%
GM growth 5Y16.63%
F-Score5
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.78%
Cap/Sales 2.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.39
Quick Ratio 1.07
Altman-Z -9.27
F-Score5
WACC9.91%
ROIC/WACCN/A
Cap/Depr(3y)20.68%
Cap/Depr(5y)155.29%
Cap/Sales(3y)4.46%
Cap/Sales(5y)45.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.58%
EPS Next Y60.39%
EPS Next 2Y36.48%
EPS Next 3Y23.6%
EPS Next 5Y13.34%
Revenue 1Y (TTM)-12.56%
Revenue growth 3Y-18.39%
Revenue growth 5Y5.6%
Sales Q2Q%-23.25%
Revenue Next Year-16.99%
Revenue Next 2Y-7.83%
Revenue Next 3Y-0.55%
Revenue Next 5Y3.39%
EBIT growth 1Y70.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year94.93%
EBIT Next 3Y27.27%
EBIT Next 5Y14.69%
FCF growth 1Y71.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y71.78%
OCF growth 3YN/A
OCF growth 5YN/A